Clinical Trials Search

Official Title: A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.

Study Purpose: To assess whether ultrasound-facilitated, catheter-directed, thrombolysis and anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization.

Status: Active, Not Recruiting

Official Title: A Multicenter, Randomized, Phase III Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With Standard of Care in Adult participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL) 

Study Purpose: To evaluate the effectiveness of IT-03 compared to the usual treatment of pazopanib, trabectedin or eribulin 

Status: Suspended

Official Title: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) Trial

Study Purpose: To evaluated safety and effectiveness of prophylactic LAAE for the prevention of ischemic stroke or systemic embolism in subjects undergoing cardiac surgery who have risk factors for AF and ischemic stroke

Status: Active, Not Recruiting

Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure

Study Purpose: To demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care on the composite endpoint of heart failure (HF) events (hospitalization for HF or urgent HF visits) or death from cardiovascular (CV) disease in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) and a body mass index (BMI) ≥ 30 kg/m2

Status: Available

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.

Status: Recruiting

Official Title: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial  

Study Purpose: To investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis and/or extracapsular extension in the SN.

Status: Recruiting

Official Title: Testing the addition of Herceptin Hylecta or Phesgo to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma.

Study Purpose: To determine if the addition of the study drugs will lower the chance of this disease from coming back.

Status: Recruiting

Official Title: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity CancerRandomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

Study Purpose: To see if neck and shoulder function and pain are better after SLN biopsy surgery compared to the usual approach and to see if SLN biopsy surgery is as good as the usual approach in extending your time without cancer.

Status: Suspended

Official Title: Testing the use of ado-trastuzumab emtansine compared to the usual treatment (chemotherapy with docetaxel plus trastuzumab) for recurrent, metastatic, or unresectable HER2-Positive salivary gland cancer.

Study Purpose: Will ado-trastuzumab emtansine extend the length of time without your cancer getting worse compared to standard of care?

Status: Recruiting

Official Title: A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Study Purpose: To determine if adding Relatlimab to Nivolumab maintenance therapy improves progression-free survival following first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma.

Status: Recruiting